Figure 3
Kaplan-Meier estimates of OS according to BIRC3 disruption. (A) Kaplan-Meier estimates of OS according to BIRC3 disruption in newly diagnosed CLL patients (n = 306). BIRC3 wild-type (WT) patients are represented by the blue line. Patients with BIRC3 disruption by mutations and/or deletions (BIRC3 dis) are represented by the red line. (B) Kaplan-Meier estimates of OS according to BIRC3 and TP53 disruption in newly diagnosed CLL patients (n = 306). BIRC3 and TP53 wild-type patients are represented by the blue line. Patients harboring BIRC3 disruption but who are wild-type on the TP53 gene (BIRC3 dis) are represented by the red line. Patients harboring TP53 disruption but who are wild-type on the BIRC3 gene (TP53 dis) are represented by the yellow line.

Kaplan-Meier estimates of OS according to BIRC3 disruption. (A) Kaplan-Meier estimates of OS according to BIRC3 disruption in newly diagnosed CLL patients (n = 306). BIRC3 wild-type (WT) patients are represented by the blue line. Patients with BIRC3 disruption by mutations and/or deletions (BIRC3 dis) are represented by the red line. (B) Kaplan-Meier estimates of OS according to BIRC3 and TP53 disruption in newly diagnosed CLL patients (n = 306). BIRC3 and TP53 wild-type patients are represented by the blue line. Patients harboring BIRC3 disruption but who are wild-type on the TP53 gene (BIRC3 dis) are represented by the red line. Patients harboring TP53 disruption but who are wild-type on the BIRC3 gene (TP53 dis) are represented by the yellow line.

Close Modal

or Create an Account

Close Modal
Close Modal